These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32183159)

  • 61. Loss of glutaredoxin 3 impedes mammary lobuloalveolar development during pregnancy and lactation.
    Pham K; Dong J; Jiang X; Qu Y; Yu H; Yang Y; Olea W; Marini JC; Chan L; Wang J; Wehrens XH; Cui X; Li Y; Hadsell DL; Cheng N
    Am J Physiol Endocrinol Metab; 2017 Mar; 312(3):E136-E149. PubMed ID: 27894063
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
    de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
    Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inhibition effect of enteropeptidase on RANKL-RANK signalling by cleavage of RANK.
    Zhao Y; Jin M; Ma J; Zhang S; Li W; Chen Y; Zhou Y; Tao H; Liu Y; Wang L; Han H; Niu G; Tao H; Liu C; Gao B
    FEBS Lett; 2013 Sep; 587(18):2958-64. PubMed ID: 23954298
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
    Wargon V; Riggio M; Giulianelli S; Sequeira GR; Rojas P; May M; Polo ML; Gorostiaga MA; Jacobsen B; Molinolo A; Novaro V; Lanari C
    Int J Cancer; 2015 Jun; 136(11):2680-92. PubMed ID: 25363551
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression of the RANK/RANKL/OPG system in the human intervertebral disc: implication for the pathogenesis of intervertebral disc degeneration.
    Sano T; Akeda K; Yamada J; Takegami N; Sudo T; Sudo A
    BMC Musculoskelet Disord; 2019 May; 20(1):225. PubMed ID: 31101043
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
    Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
    J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Anti-RANKL antibody].
    Omiya T; Tanaka S
    Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Targeting RANKL in breast cancer: bone metastasis and beyond.
    Azim H; Azim HA
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Bone metastasis and RANKL].
    Nakashima T
    Clin Calcium; 2014 Aug; 24(8):1201-8. PubMed ID: 25065872
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration.
    Hsu CJ; Lin TY; Kuo CC; Tsai CH; Lin MZ; Hsu HC; Fong YC; Tang CH
    J Cell Biochem; 2010 Sep; 111(1):138-47. PubMed ID: 20506523
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
    Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
    Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
    [TBL] [Abstract][Full Text] [Related]  

  • 73. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis.
    Schramek D; Sigl V; Penninger JM
    Trends Endocrinol Metab; 2011 May; 22(5):188-94. PubMed ID: 21470874
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells.
    Lee HJ; Gallego-Ortega D; Ledger A; Schramek D; Joshi P; Szwarc MM; Cho C; Lydon JP; Khokha R; Penninger JM; Ormandy CJ
    Development; 2013 Apr; 140(7):1397-401. PubMed ID: 23462470
    [TBL] [Abstract][Full Text] [Related]  

  • 75. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
    Palafox M; Ferrer I; Pellegrini P; Vila S; Hernandez-Ortega S; Urruticoechea A; Climent F; Soler MT; Muñoz P; Viñals F; Tometsko M; Branstetter D; Dougall WC; González-Suárez E
    Cancer Res; 2012 Jun; 72(11):2879-88. PubMed ID: 22496457
    [TBL] [Abstract][Full Text] [Related]  

  • 76. RANKLed by the Complexity of Signaling in Breast Cancer Metastasis to the Brain.
    Wang K; Hackney JR; Siegal GP; Wei S
    Clin Breast Cancer; 2020 Oct; 20(5):e569-e575. PubMed ID: 32381383
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
    Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MPA influences tumor cell proliferation, migration, and invasion induced by RANKL through PRB involving the MAPK pathway in endometrial cancer.
    Wang J; Sun X; Zhang H; Wang Y; Li Y
    Oncol Rep; 2015 Feb; 33(2):799-809. PubMed ID: 25483570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.